
Intellipharmaceutics shares crushed as FDA experts snub pain drug; Moncef Slaoui joins Moderna board
→ After getting chastised by regulators in an internal FDA review of Toronto-based Intellipharmaceutics‘ $IPCI new pain drug Rexista, a panel of outside experts joined in, voting to recommend a rejection of the therapy. Billed as a new version of oxy with new features which the biotech claimed would deter abuse, the panelists voted 22 to 1 against an OK. And all of them agreed that the company never offered the data that would be needed to gain an abuse-deterrent note on the label, if it were to be approved. The company’s shares cratered, dropping 45%.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.